Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 671

Sort by

Sort Order Select

Journal Articles

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Deborah M. Stephens, John C. Byrd

Blood (2021) 138 (13): 1099–1109.

https://doi.org/10.1182/blood.2020006783

Published: 2021

Journal Articles

BCL2 and MCL1 inhibitors for hematologic malignancies

Andrew W. Roberts, Andrew H. Wei, David C. S. Huang

Blood (2021) 138 (13): 1120–1136.

https://doi.org/10.1182/blood.2020006785

Published: 2021

Journal Articles

CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues

Xiaobing Yu, Leonel Munoz-Sagredo, Karolin Streule, Patricia Muschong, Elisabeth Bayer, Romina J. Walter, Julia C. Gutjahr, Richard Greil, Miguel L. Concha, Carsten Müller-Tidow, Tanja N. Hartmann, Véronique Orian-Rousseau

Blood (2021) 138 (12): 1067–1080.

https://doi.org/10.1182/blood.2020006343

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

How I treat pediatric acute myeloid leukemia

Jeffrey E. Rubnitz, Gertjan J. L. Kaspers

Blood (2021) 138 (12): 1009–1018.

https://doi.org/10.1182/blood.2021011694

Published: 2021

Journal Articles

To start and stop or just keep going?

John G. Gribben

Blood (2021) 138 (10): 819–820.

https://doi.org/10.1182/blood.2021012675

Published: 2021

Journal Articles

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Shuo Ma, John F. Seymour, Danielle M. Brander, Thomas J. Kipps, Michael Y. Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W. Roberts

Blood (2021) 138 (10): 836–846.

https://doi.org/10.1182/blood.2020009578

Published: 2021

Includes: Supplemental data

Journal Articles

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Maria Teresa Voso, Giulia Falconi, Emiliano Fabiani

Blood (2021) 138 (9): 749–757.

https://doi.org/10.1182/blood.2021010764

Published: 2021

Journal Articles

How I treat chronic lymphocytic leukemia after venetoclax

Thomas E. Lew, Constantine S. Tam, John F. Seymour

Blood (2021) 138 (5): 361–369.

https://doi.org/10.1182/blood.2020008502

Published: 2021

Journal Articles

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production

Jong Bok Lee, Dilshad H. Khan, Rose Hurren, Mingjing Xu, Yoosu Na, Hyeonjeong Kang, Sara Mirali, Xiaoming Wang, Marcela Gronda, Yulia Jitkova, Neil MacLean, Andrea Arruda, Zoe Alaniz, Marina Y. Konopleva, Michael Andreeff, Mark D. Minden, Li Zhang, Aaron D. Schimmer

Blood (2021) 138 (3): 234–245.

https://doi.org/10.1182/blood.2020009081

Published: 2021

Includes: Supplemental data

Journal Articles

Sensitivity to venetoclax: the B-side of myeloma?

Cyrille Touzeau, Philippe Moreau

Blood (2021) 137 (26): 3582–3583.

https://doi.org/10.1182/blood.2021011146

Published: 2021

Journal Articles

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Vikas A. Gupta, Benjamin G. Barwick, Shannon M. Matulis, Ryosuke Shirasaki, David L. Jaye, Jonathan J. Keats, Benjamin Oberlton, Nisha S. Joseph, Craig C. Hofmeister, Leonard T. Heffner, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, Constantine S. Mitsiades, Jonathan L. Kaufman, Lawrence H. Boise

Blood (2021) 137 (26): 3604–3615.

https://doi.org/10.1182/blood.2020007899

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia

Blood (2021) 137 (26): 3641–3655.

https://doi.org/10.1182/blood.2020007651

Published: 2021

Includes: Supplemental data

Journal Articles

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Blood (2021) 137 (25): 3495–3506.

https://doi.org/10.1182/blood.2020007303

Published: 2021

Includes: Supplemental data

Journal Articles

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

Blood (2021) 137 (25): 3507–3517.

https://doi.org/10.1182/blood.2020008201

Published: 2021

Includes: Supplemental data

Journal Articles

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti

Blood (2021) 137 (24): 3378–3389.

https://doi.org/10.1182/blood.2020010187

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu, Irit Avivi, Anat Aharon, Gabi Shefer, Shai Levi, Yotam Bronstein, Miguel Morales, Tomer Ziv, Yamit Shorer Arbel, Lydia Scarfò, Erel Joffe, Chava Perry, Paolo Ghia

Blood (2021) 137 (23): 3165–3173.

https://doi.org/10.1182/blood.2021011568

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Scott Boiko, Theresa Proia, Maryann San Martin, Gareth P. Gregory, Michelle Min Wu, Neeraj Aryal, Maureen Hattersley, Wenlin Shao, Jamal C. Saeh, Stephen E. Fawell, Ricky W. Johnstone, Lisa Drew, Justin Cidado

Blood (2021) 137 (21): 2947–2957.

https://doi.org/10.1182/blood.2020008528

Published: 2021

Includes: Supplemental data

Journal Articles

What can Heraclitus tell us about AML?

Arnold Ganser

Blood (2021) 137 (20): 2719–2720.

https://doi.org/10.1182/blood.2021011264

Published: 2021

Journal Articles

Targeting MCL-1 and BCL-2: a 1-2 punch

Jennifer R. Brown

Blood (2021) 137 (20): 2711–2712.

https://doi.org/10.1182/blood.2021012001

Published: 2021

Journal Articles

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Blood (2021) 137 (20): 2721–2735.

https://doi.org/10.1182/blood.2020010167

Published: 2021

Includes: Supplemental data

NARROW

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

BCL2 and MCL1 inhibitors for hematologic malignancies

CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues

How I treat pediatric acute myeloid leukemia

To start and stop or just keep going?

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

How I treat chronic lymphocytic leukemia after venetoclax

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production

Sensitivity to venetoclax: the B-side of myeloma?

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

What can Heraclitus tell us about AML?

Targeting MCL-1 and BCL-2: a 1-2 punch

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only